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COMPOSITIONS AND METHODS USEFUL 
FOR TREATING CIRCULATORY AND 
HYPOVOLEMIC SHOCK 
RELATED APPLICATIONS 
This application claims priority from US. Provisional 
Application Ser. No. 60/910,774 ?led Apr. 9, 2007, the entire 
disclosure of Which is incorporated herein by this reference. 
GOVERNMENT INTEREST 
This invention Was made, in part, With government support 
from the US Of?ce of Naval Research (ONR) “Opioid-like 
Hibernation Factors Provide Cerebral Ischemic Protection” 
(Account No. 4-6431). The government has certain rights in 
the invention. 
BACKGROUND 
Circulatory shock and hypovolemic shock are commonly 
occurring threatening pathophysiological states, Which can 
occur secondary to trauma, hemorrhage, burns, sepsis, aller 
gic reactions, and heart failure. Shock-like microcirculatory 
abnormalities are also associated With certain procedures, 
such as surgical procedures. Such shock, Whether systemic or 
localiZed, is characterized by a reduction in blood pressure, 
blood ?oW, and/or blood volume, and can cause an insu?i 
cient supply of blood and oxygen to vital organs and tissues. 
This insuf?cient blood and oxygen supply can cause local 
hypoxia, ischemia, and can lead to loss of cellular and organ 
function and even death. 
Currently-available treatments for circulatory and hypov 
olemic shock include forms of volume infusion. For example, 
the standard of care in initial management of hemorrhagic 
shock is rapid administration of large volumes ?uids, several 
liters in an adult patient. A preferred ?uid is Ringer’ s lactate, 
although normal saline or other similar isotonic crystalloid 
solutions are also used. The standard continued treatment is 
based on an observed response to the initial ?uid therapy. 
Guidelines generally provide that up to 300 ml of electrolyte 
solution is required for each 100 ml of blood lost (“three for 
one” rule). For blood losses up to 30% of circulation blood 
volume, crystalloid alone Will often su?ice; hoWever, With 
ongoing blood loss, or a more signi?cant hemorrhage, prompt 
surgical intervention or blood therapy becomes necessary. 
Over the last decade, this standard approach has been reex 
amined, leading to the conclusion that changes are needed in 
current resuscitation strategies used by ?rst responders to 
trauma settings and by medical personnel in emergency 
rooms (ER) and intensive care units (ICU). There are multiple 
reasons for this conclusion. 
First, the clinical trajectory of patients Who develop mul 
tiple organ failure is set early in the resuscitation process (i.e., 
Within about 6 hr of an event that creates a risk of shock, such 
as an injury resulting in hemorrhaging). Many patients at high 
risk require emergency surgery or interventional radiology, 
and arrive in an ICU after this time WindoW. Although resus 
citation efforts in the ICU can clearly modify the subsequent 
clinical course for the patient, even highly re?ned and indi 
vidually tailored resuscitation cannot reverse the dysfunc 
tional response that has already occurred. As such, currently 
used resuscitation strategies do not adequately limit the 
incidence of multiple organ failure. 
Second, although initial crystalloidvolume loading is valu 
able in de?ning hemodynamic stability, to continue this pro 
cess in the face of ongoing hemorrhaging promotes further 
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bleeding, hemodilutes the patient, and sets the stage for hypo 
thermia, acidosis, and coagulopathy. This syndrome is par 
ticularly problematic in patients With blunt trauma, Who often 
have sources of bleeding that are not amenable to direct 
control. Failure to resuscitate these patients Will, hoWever, 
ultimately lead to irreversible shock. As such, currently used 
resuscitation strategies can actually exacerbate ischemic 
injury. 
Third, although crystalloid resuscitation is ef?cacious in 
most patients, it produces problematic tissue edema in 
patients Who arrive to an ICU in severe shock. These patients 
typically need massive ?uid resuscitation to maintain intra 
vascular volume and many develop abdominal compartment 
syndrome, Which creates increased risks for multiple organ 
failure. Patients With severe torso trauma Who are admitted 
With shock and an associated severe closed head injury are in 
a precarious situation. Under-resuscitation decreases cerebral 
perfusion pressure, Which causes secondary brain injury. 
Excessive crystalloid administration promotes cerebral 
edema, Which increases intracranial pressure and further 
decrease cerebral perfusion pressure. As such, currently used 
resuscitation strategies can exacerbate injury. 
Fourth, shock initiates dysfunctional in?ammation that 
causes multiple organ failure. Resuscitation is an obligatory 
intervention to decrease the severity of the shock insult, but 
current strategy is not directed at modulating in?ammation, in 
fact, it may Worsen it. Laboratory studies shoW that lactated 
Ringer’s solution activates neutrophils. Even more disturbing 
is an observation that blood transfusion contains proin?am 
matory mediators that both prime and activate neutrophils. As 
such, currently used resuscitation strategies can exacerbate 
injury. 
Prospective randomiZed controlled trials studying cur 
rently-used resuscitation strategies (crystalloid and colloid 
resuscitation) Were conducted in the 1970s and 1980s, before 
the recognition of abdominal compartment syndrome as an 
important clinical entity. Additionally, albumin Was the prin 
cipal colloid used, but other types of colloid, such as starches 
and gelatins, are available and are noW being used in resus 
citation. Because of their higher molecular Weights, colloids 
such as starches and gelatins are con?ned to the intravascular 
space, and their infusion results in more e?icient plasma 
volume expansion. In severe hemorrhagic shock, hoWever, 
the permeability of capillary membranes increases, alloWing 
colloids to enter the interstitial space, Which can then Worsen 
edema and impair tissue oxygenation. Although it has been 
suggested that these high-molecular-Weight agents could 
plug capillary leaks that occur during neutrophil-mediated 
organ injury, it has not been established that such a bene?t 
could result from their use. 
It has also been proposed that resuscitation With albumin 
induces renal failure and even impairs pulmonary function. 
Similarly, hetastarch has been shoWn to induce renal dysfunc 
tion in patients With septic shock and in recipients of kidneys 
from brain-dead donors. Hetastarch also has a limited role in 
massive resuscitation because it causes a coagulopathy and 
hyperchloremic acidosis due to its high chloride content. A 
neW hydroxyethyl starch (HES) preparation (e.g., HEX 
TEND®) purportedly does not cause these adverse effects, 
but has not been studied in massive resuscitation. It is noW 
thought that colloids might reduce the incidence of abdomi 
nal compartment syndrome, but this possible bene?t must be 
Weighed against the potentially detrimental effects of colloids 
already reported. 
Results of numerous studies indicate that HES administra 
tion can lead to reduction in circulating factor VII and von 
Willebrand factor levels, impairment of platelet function, 
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prolongation of partial thromboplastin time and activated 
partial thromboplastin time, and increase in bleeding compli 
cations. Coagulopathy and hemorrhage associated With HES 
are often encountered in cardiac surgery, a setting in Which 
susceptibility to such complications is heightened by tran 
sient acquired platelet dysfunction resulting from the proce 
dure. Thus, in cardiac surgery studies With albumin as the 
control, HES has resulted in platelet depletion and dysfunc 
tion, prothrombin time and activated partial thromboplastin 
time prolongation, and increased postoperative bleeding. 
Dextran, as compared With albumin, has been shoWn to 
reduce platelets and increase postoperative bleeding in car 
diac surgery patients. Postoperative blood loss Was early cor 
related With the volume of gelatin used to prime the extracor 
poreal circuit. Arti?cial colloids, including dextran, 
hetastarch and pentastarch, have been associated With renal 
impairment, and HES has been demonstrated to increase sen 
sitive markers of renal tubule damage in surgical patients. In 
a study of sepsis patients, HES exposure Was recently shoWn 
to be an independent risk factor for acute renal failure. In the 
renal transplantation setting, HES has been found to reduce 
urinary output, increase creatinine levels and dopamine 
requirement, and increase the need for hemodialysis or hemo 
dia?ltration. 
Studies have suggested that both over- and under-resusci 
tation can increase mortality. Early aggressive ?uid resusci 
tation can be deleterious, according to a clinical trail in Which 
mortality Was reduced by delaying ?uid therapy. Also, there 
are several practical and logistic limitations to the current 
methods of prehospital resuscitation, Which include limita 
tions on the amount of ?uid that can be delivered due to 
inadequate i.v. bore size and limited availability of ?uid in the 
?eld, e. g. combat casualty care. Hypotensive resuscitation is 
one approach that has been advocated as a better means to 
perform ?eld resuscitation of penetrating trauma. HoWever, 
early application of aggressive resuscitation has been shoWn 
to affect outcomes deleteriously in animal models of uncon 
trolled hemorrhage, in Which aggressive resuscitation using a 
variety of ?uids caused rapid increases in blood pressure, 
internal bleeding, and higher mortality. 
In the early 1980s research interest in hypertonic saline Was 
spurred. Small-volume hypertonic saline Was shoWn to be as 
effective as large-volume crystalloids in expanding plasma 
volume and enhancing cardiac output in hemorrhagic shock 
in animals. Furthermore, hypertonic saline increased perfu 
sion of the microcirculation, presumably by selective arteri 
olar vasodilation and by decreasing sWelling of red blood 
cells and of the endothelium. This improved microcircula 
tion, hoWever, could lead to increased bleeding. Conse 
quently, hypertonic saline Was tested in animal models of 
uncontrolled hemorrhagic shock and Was shoWn to increase 
bleeding, but mortality Was model-dependent and the best 
survival Was obtained When saline Was given With high-vol 
ume crystalloids. Additionally, the resuscitative effectiveness 
of hypertonic saline Was found to be enhanced by combina 
tion With dextran (hypertonic saline dextran (HSD)). In vieW 
of the small volume needed to achieve these effects, there Was 
great interest in the use of these ?uids in resuscitation in the 
?eld for both military and civilian use. 
From the late 1980s through the early 1990s, several trials 
Were done. Individually, these trials found survival outcome 
to be inconsistently improved, but did document that a bolus 
of hypertonic saline or HSD Was safe. Meta-analysis of these 
data suggests that hypertonic saline is no better than standard 
of care isotonic crystalloid ?uids, but that HSD might be 
better. Subgroup analysis shoWed that patients Who presented 
With shock and concomitant severe closed head injury ben 
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e?ted most from HSD. This observation Was consistent With 
laboratory data shoWing that, compared With isotonic crys 
talloid, hypertonic saline or HSD increases cerebral perfusion 
pressure, decreases intracranial pressure, and decreases brain 
edema, in combined head injury and hemorrhagic shock. This 
?nding has led some authorities to recommend that hyper 
tonic saline should replace mannitol in the management of 
intracranial hypertension in patients With severe closed head 
injury. The argument in favor of hypertonic saline is even 
more compelling With the recent recognition that hypertonic 
saline resuscitation decreases the in?ammatory response 
(speci?cally neutrophil cytotoxicity) in animal models of 
hemorrhagic shock, ischemia and reperfusion, and sepsis. 
More recent studies have compared hypotensive and nor 
motensive resuscitation of hemorrhage using lactated Ring 
er’s (LR) With hypotensive resuscitation using HEXTEND® 
(Hex) 6% hetastarch in isotonic buffered saline in a multi 
hemorrhage sheep model. Hypotensive resuscitation With LR 
greatly reduced volume requirements as compared With nor 
motensive resuscitation, and Hex achieved additional volume 
sparing. HoWever, trends toWard loWer base excess (BE) val 
ues and loW levels of urinary ?oW in some animals in both 
hypotensive treatment protocols and the occurrence of deaths 
only in the hypotensive treatment protocols suggest that 
resuscitation to a target MAP of 65 mmHg may be too loW for 
optimal outcomes. Hypotensive resuscitation regimens may 
reduce bleeding but do not optimally restore metabolic func 
tion. 
To summarize, currently-available treatments for circula 
tory and hypovolemic shock focus on various forms of vol 
ume infusion. Intravenous ?uids appear to improve hemody 
namic indices in the short term, but most also have adverse 
consequences on hemostatic mechanisms. Indeed, it is noW 
becoming clear that resuscitation ?uids may actually poten 
tiate cellular injury via severe immune activation and upregu 
lation of cellular injury markers that can result in exacerba 
tion of blood loss. Bleeding can also be enhanced by 
injudicious ?uid administration as a consequence of dilu 
tional coagulopathy and secondary clot disruption from 
increased blood ?oW, increased perfusion pressure, and 
decreased blood viscosity. 
Accordingly, there remains a need in the art for a method of 
treating circulatory and hypovolemic shock, Which avoids the 
above-identi?ed problems. 
SUMMARY 
The present invention meets some or all of the above 
identi?ed needs, as Will become evident to those of ordinary 
skill in the art after a study of information provided in this 
document. This Summary describes several embodiments of 
the presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
Summary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative features 
of a given embodiment is likeWise exemplary. Such an 
embodiment can typically exist With or Without the feature(s) 
mentioned; likeWise, those features can be applied to other 
embodiments of the presently-disclosed subject matter, 
Whether listed in this Summary or not. To avoid excessive 
repetition, this Summary does not list or suggest all possible 
combinations of such features. 
The present invention relates to the use of an isolated 
polypeptide, compositions and methods for treating shock 
associated With a reduction of blood volume, or an insu?i 
cient supply of blood to an organ or tissue. The method alloWs 
bleeding to be controlled, While providing effective hemody 
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namic and metabolic support. The method can be practiced 
Without making use of resuscitation ?uids, Which have been 
associated With various disadvantages and risks. The method 
of the present invention can be used for treating shock that is 
characterized by a state of Whole body ischemia. The method 
of the present invention can be used for treating circulatory 
and hypervolemic shock, such as hemorrhagic shock, and 
injuries resulting from such shock, such as injuries to an organ 
or tissue due to an inadequate supply of oxygen being deliv 
ered to the organ or tissue. 
Disclosed herein is an isolated polypeptide, comprising the 
amino acid sequence Tyr-(D-Ala)-Phe-Ala-Ile-Gly-Asp 
Phe-Ser-Ile-NH2 (SEQ ID NO: 1), Which is referred to herein 
as Deltorphin-E or Delt-E. Amino acids can occur in tWo 
possible optical isomers, D isomers and L isomers. D-Ala 
refers to a D-isomer of alanine. Also disclosed herein is a 
biologically active Deltorphin-E polypeptide, including an 
amino acid sequence having at least about 90% or greater 
homology to SEQ ID NO: 1. Also disclosed herein is a bio 
logically active Deltorphin-E polypeptide, including an 
amino acid sequence encoded by a nucleic acid sequence 
having at least about 90% or greater homology to the nucleic 
acid sequence TAnl GCn3 TTnl GCn3 ATn2 GGn3 GAnl 
TTnl AGnl ATn2 (SEQ ID NO: 2), Where n1 is T or C; n2 is T, 
C, or A; and n3 is T, C, A, or G. Also disclosed herein are 
pharmaceutical compositions, including a pharmaceutically 
effective amount of a Deltorphin-E polypeptide, and a phar 
maceutically acceptable carrier. 
An exemplary method of the present invention includes 
administering an effective amount of a Deltorphin-E 
polypeptide in a pharmaceutically acceptable formulation. 
The polypeptide can be administered concurrently With or 
before the onset of shock or the occurrence of an event that 
creates a risk of shock. The polypeptide can be administered 
up to about 24 hours before the onset of shock or the occur 
rence of the event. The polypeptide can be administered sub 
sequent to the onset of shock or the occurrence of an event that 
creates a risk of shock. The polypeptide can be administered 
up to about 4 hours subsequent to the occurrence of an event 
that creates a risk of shock. 
The event creating a risk of shock can be, for example, 
hemorrhage or a planned surgery. Examples of planned sur 
geries include planned ischemia, heart valve replacement 
surgery, coronary artery bypass graft surgery, stint placement 
surgery, orthopedic surgery, organ repair surgery, organ trans - 
plantation surgery, and a surgery to implant a device. 
An effective amount of the polypeptide can be adminis 
tered in accordance With an exemplary method such that one 
or more desired effects are produced. A desired effect can be 
a prophylactic effect. A desired effect can be a therapeutic 
effect. In certain embodiments, treatment using the polypep 
tide can produce one or more prophylactic effects and one or 
more therapeutic effects. Examples of prophylactic effects 
include preventing or reducing the risk of shock, and prevent 
ing or reducing the risk of injuries resulting from shock. 
Examples of therapeutic effects include curing or mitigating 
shock, and restoring perfusion to organs and tissues. 
DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graph comparing dose-dependent recovery of 
mean arterial pressure (MAP, mmHg) as a function of time for 
Delt-E-treated groups and control group, Where treatment 
Was immediately after severe hemorrhage. 
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FIG. 2 is a bar graph comparing the time of survival for 
Delt-E-treated groups at three different doses and control 
group, Where treatment Was immediately after severe hemor 
rhage. 
FIG. 3 is a graph of the average heart rate gain post-severe 
hemorrhage after treatment With saline or 5.5 mg/kg Delt-E. 
FIG. 4 is a graph comparing lactate levels (mmol/l), in 
arterial blood sampled at the beginning and end of hemor 
rhage for control group and Delt-E-treated groups at three 
different doses Where treatment Was immediately after severe 
hemorrhage. 
FIG. 5 is a bar graph comparing the Delt-E dose response 
postinj ection pulse pressure (difference betWeen systolic and 
diastolic pressure). 
FIG. 6 is a graph of the Delt-E dose response postinj ection 
comparison of pH versus survival time. 
FIG. 7 is a graph comparing mean arterial pressure (MAP, 
mmHg) as a function of time for Delt-E-treated and control 
groups Where treatment Was prior to hemorrhage. 
FIG. 8 is a graph comparing average heart rates (HR, 
beats/minute) as a function of time for Delt-E-treated and 
control groups, Where treatment Was prior to hemorrhage. 
FIG. 9 is a graph comparing the percentage of survivors for 
Delt-E-treated and control groups as a function of time, Where 
treatment Was prior to hemorrhage. 
FIG. 10 is a graph comparing lactate levels (mmol/L) in 
arterial blood samples at the beginning of hemorrhage and at 
the end of hemorrhage for Delt-E-treated and control groups 
Where treatment Was prior to hemorrhage. 
BRIEF DESCRIPTION OF THE SEQUENCE 
LISTING 
SEQ ID NO: 1 is an isolated polypeptide Deltorphin-E 
(Delt-E), including the folloWing amino acid sequence: Tyr 
(D-Ala)-Phe-Ala-Ile-Gly-Asp-Phe-Ser-Ile-NH2. 
SEQ ID NO: 2 is an isolated nucleic acid molecule, includ 
ing the folloWing nucleic acid sequence: TAnl GCn3 TTnl 
GCn3 ATn2 GGn3 GAnl TTnl AGnl ATn2, Where n1 is T or C; 
n2 is T, C, orA; and n3 is T, C, A, or G. 
DESCRIPTION OF EMBODIMENTS OF THE 
INVENTION 
The details of one or more embodiments of the present 
invention are set forth in this document. Modi?cations to 
embodiments described in this document, and other embodi 
ments, Will be evident to those of ordinary skill in the art after 
a study of the information provided in this document. The 
information provided in this document, and particularly the 
speci?c details of the described exemplary embodiments, is 
provided primarily for clearness of understanding and no 
unnecessary limitations are to be understood therefrom. In 
case of con?ict, the speci?cation of this document, including 
de?nitions, Will control. 
While the folloWing terms are believed to be Well under 
stood by one of ordinary skill in the art, the folloWing de?ni 
tions are set forth to facilitate explanation of the present 
invention. 
Unless de?ned otherWise, all technical and scienti?c terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art. Although any methods, 
devices, and materials similar or equivalent to those described 
herein can be used in the practice or testing of the presently 
disclosed subject matter, representative methods, devices, 
and materials are noW described. 
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Unless otherwise indicated, all numbers expressing quan 
tities of ingredients, properties such as reaction conditions, 
and so forth used in the speci?cation and claims are to be 
understood as being modi?ed in all instances by the term 
“about”. Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this speci?cation and claims 
are approximations that can vary depending upon the desired 
properties sought to be obtained by the presently-disclosed 
subject matter. 
As used herein, the term “about,” When referring to a value 
or to an amount of mass, Weight, time, volume, concentration 
or percentage is meant to encompass variations of in some 
embodiments 120%, in some embodiments 110%, in some 
embodiments 15%, in some embodiments 11%, in some 
embodiments 10.5%, and in some embodiments 10.1% from 
the speci?ed amount, as such variations are appropriate to 
perform the disclosed method. 
As used herein, the term “biologically active” refers to an 
ability to affect treatment for the disease state being treated 
When provided in an effective amount. 
As used herein, the terms “effective amount” and “thera 
peutically effective amount” are used interchangeably and 
mean a dosage su?icient to provide treatment for the disease 
state being treated. The exact amount that is required Will vary 
from subject to subject, depending on the species, age, and 
general condition of the subject, the particular carrier or adju 
vant being used, mode of administration, and the like. As 
such, the effective amount Will vary based on the particular 
circumstances, and an appropriate effective amount can be 
determined in a particular case by one of ordinary skill in the 
art using only routine experimentation. 
The term “nucleic acid” refers to deoxyribonucleotides or 
ribonucleotides and polymers thereof in either single- or 
double-stranded form. Unless speci?cally limited, the term 
encompasses nucleic acids containing knoWn analogues of 
natural nucleotides that have similar binding properties as the 
reference nucleic acid and are metaboliZed in a manner simi 
lar to naturally occurring nucleotides. Unless otherWise indi 
cated, a particular nucleic acid sequence also implicitly 
encompasses conservatively modi?ed variants thereof (e.g., 
degenerate codon substitutions) and complementary 
sequences and as Well as the sequence explicitly indicated. 
Speci?cally, degenerate codon substitutions can be achieved 
by generating sequences in Which the third position of one or 
more selected (or all) codons is substituted With mixed-base 
and/or deoxyinosine residues (BatZer et al. (1991) Nucleic 
Acid Res 1915081; Ohtsuka et al. (1985) JBiol Chem 260: 
2605-2608; Rossolini et al. (1 994) Mol Cell Probes 8:91-98). 
The terms “nucleic acid” or “nucleic acid sequence” can also 
be used interchangeably With gene, open reading frame 
(ORF), cDNA, and mRNA encoded by a gene. 
As used herein, the term “polypeptide” means any polymer 
comprising any of the 20 protein amino acids, regardless of its 
siZe. Although “protein” is often used in reference to rela 
tively large polypeptides, and “peptide” is often used in ref 
erence to small polypeptides, usage of these terms in the art 
overlaps and varies. The term “polypeptide” as used herein 
refers to peptides, polypeptides and proteins, unless other 
Wise noted. As used herein, the terms “protein,” “polypep 
tide,” and “peptide” are used interchangeably herein When 
referring to a gene product. Unless otherWise indicated, a 
particular polypeptide also implicitly encompasses conserva 
tively-substituted variants thereof. 
The term “conservatively substituted variant” refers to a 
polypeptide comprising an amino acid residue sequence sub 
stantially identical to the sequence of a polypeptide Whose 
sequence is disclosed herein, in Which one or more residues 
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have been conservatively substituted With a functionally 
similar residue, and Which is biologically active. The phrase 
“conservatively-substituted variant” also includes polypep 
tides Wherein a residue is replaced With a chemically-deriva 
tiZed residue, provided that the resulting polypeptide is bio 
logically active. Examples of conservative substitutions 
include the substitution of one non-polar (hydrophobic) resi 
due, such as isoleucine, valine, leucine, or methionine for 
another; the substitution of one polar (hydrophilic) residue 
for another, such as betWeen arginine and lysine, betWeen 
glutamine and asparagine, betWeen glycine and serine; the 
substitution of one basic residue such as lysine, arginine, or 
histidine for another; or the substitution of one acidic residue, 
such as aspartic acid or glutamic acid for another. 
The term “isolated”, Whenused in the context of an isolated 
polypeptide, is a polypeptide that, by the hand of man, exists 
apart from its native environment and is therefore not a prod 
uct of nature. An isolated polypeptide can exist in a puri?ed 
form or can exist in a non-native environment such as, for 
example, in a transgenic host cell. 
Disclosed herein are polypeptides, compositions, and 
methods useful for treating shock associated With a reduction 
of blood volume, or an insuf?cient supply of bloodto an organ 
or tissue. For example, the compositions and methods of the 
present invention may be used for treating circulatory and 
hypovolemic shock, such as hemorrhagic shock, and injuries 
resulting from such shock, such as injuries to an organ or 
tissue due to an inadequate supply of oxygen being delivered 
to the organ or tissue. 
The present invention includes an isolated Deltorphin-E 
(Delt-E) polypeptide, comprising the amino acid sequence 
Tyr-(D-Ala)-Phe-Ala-lle-Gly-Asp-Phe-Ser-lle-NH2 (SEQ 
ID NO: 1). Amino acids can occur in tWo possible optical 
isomers, D isomers and L isomers. D-Ala refers to a D-isomer 
of alanine. In certain embodiments, Delt-E has a molecular 
Weight of about 1102.3 daltons. In certain embodiments, a 
biologically active Deltorphin-E polypeptide includes an 
amino acid sequence having at least about 90% or greater 
homology to SEQ ID NO: 1. In certain embodiments, a bio 
logically active Deltorphin-E polypeptide includes an amino 
acid sequence encoded by a nucleic acid sequence having at 
least about 90% or greater homology to the nucleic acid 
sequence TAnl GCn3 TTnl GCn3 ATn2 GGn3 GAnl TTnl 
AGnl ATn2 (SEQ ID NO: 2), Where n1 is T or C; 112 is T, C, or 
A; and n3 is T, C, A, or G. The Deltorphin-E polypeptide can 
be produced by a number of methods known to those skilled 
in the art, such as methods using an automated peptide syn 
thesiZer or through recombinant molecular biology tech 
niques. 
The present invention includes compositions comprising a 
pharmaceutically effective amount of a Deltorphin-E 
polypeptide, and a pharmaceutically acceptable carrier. 
Exemplary compositions can include a pharmaceutically 
acceptable carrier. Suitable formulations include aqueous and 
non-aqueous sterile injection solutions that can contain anti 
oxidants, buffers, bacteriostats, bactericidal antibiotics and 
solutes that render the formulation isotonic With the bodily 
?uids of the intended recipient; and aqueous and non-aqueous 
sterile suspensions, Which can include suspending agents and 
thickening agents. The compositions can take such forms as 
suspensions, solutions or emulsions in oily or aqueous 
vehicles, and can contain formulatory agents such as sus 
pending, stabiliZing and/or dispersing agents. Alternatively, 
Delt-E can be in poWder form for constitution With a suitable 
vehicle before use. 
The formulations can be presented in unit-dose or multi 
dose containers, for example sealed ampoules and vials, and 
US 7,705,119 B1 
can be stored in a frozen or freeZe-dried (lyophiliZed) condi 
tion requiring only the addition of sterile liquid carrier imme 
diately prior to use. 
In certain embodiments, Delt-E can be formulated for 
administration in an aqueous-based liquid, such as phos 
phate-buffered saline, to form an emulsion. For example, 
Delt-E can be solubiliZed in a solution including ethanol, 
propylene glycol, and 1N NaOH in a 1:111 ratio, or formu 
lated in an organic liquid such as hydroxy-propyl-beta-cyclo 
dextrin to form a solution. An appropriate amount of Delt-E 
can be solubiliZed in about 100 pl of the ethanol/propylene 
glycol/NaOH solution or hydroxy-propyl-beta-cyclodextrin. 
A desired concentration of Delt-E can be obtained by adding 
sterile physiological saline, phosphate buffered saline, or lac 
tated Ringer’s solution. The initial alkaline pH can be 
adjusted to a desired pH using, for example, 1N HCl. The pH 
can be adjusted to betWeen about 7.35 and about 7.45, or 
about 7.4. 
The present invention includes methods for treating shock 
associated With a reduction of blood volume, or an insu?i 
cient supply of blood to an organ or tissue using Delt-E. For 
example, states of Whole body ischemia, as occurs in hemor 
rhagic shock, can be treated using methods of the present 
invention. For another example, methods of the present inven 
tion can be used to provide extended pharmacological 
ischemic preconditioning (PPC) in hemorrhagic shock. The 
methods can be practiced Without the use of volume infusion 
(i.e., Without the use of resuscitation ?uids). 
For purposes of simplicity, When the term “shock” is used 
herein, unless otherWise indicated, it is used to describe cir 
culatory or ischemic shock, hypervolemic shock, hemor 
rhagic shock, or other types of shock associated With a reduc 
tion of blood volume in an organ or tissue, or an insuf?cient 
supply of blood to an organ or tissue. 
Shock that can be treated in accordance With the present 
invention can occur in a number of situations. For example, an 
event that creates a risk of shock can occur in civilian and 
military trauma settings, such as hemorrhage creating a risk 
of hemorrhagic shock. For another example, an event such as 
a planned surgery can create a risk of shock. Examples of such 
surgeries include, heart valve replacement surgeries, coro 
nary artery bypass graft surgeries, stint placement surgeries, 
orthopedic surgeries, organ repair surgeries, organ transplan 
tation surgeries, surgeries to implant devices, and the like. 
An exemplary method of the present invention for treating 
shock in a subject includes administering an effective amount 
of Delt-E to the subject. As used herein, the term “subject” 
includes both human and animal subjects. Thus, the disclosed 
methods can have veterinary therapeutic uses. As such, the 
presently disclosed subject matter provides for the treatment 
of mammals such as humans, as Well as those mammals of 
importance due to being endangered, such as Siberian tigers; 
of economic importance, such as animals raised on farms for 
consumption by humans; and/or animals of social importance 
to humans, such as animals kept as pets or in ZOOS. Examples 
of such animals include but are not limited to: camivores such 
as cats and dogs; sWine, including pigs, hogs, and Wild boars; 
ruminants and/ or ungulates such as cattle, oxen, sheep, 
giraffes, deer, goats, bison, and camels; and horses. Also 
provided is the treatment of birds, including the treatment of 
those kinds of birds that are endangered and/ or kept in Zoos, 
as Well as foWl, and more particularly domesticated foWl, i.e., 
poultry, such as turkeys, chickens, ducks, geese, guinea foWl, 
and the like, as they are also of economic importance to 
humans. Thus, also provided is the treatment of livestock, 
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including, but not limited to, domesticated sWine, ruminants, 
ungulates, horses (including race horses), poultry, and the 
like. 
Treatment can be affected in accordance With the present 
invention before, concurrently With, or after an event that 
creates a risk of shock, such as hemorrhage. Treatment can be 
affected in accordance With the present invention before, 
concurrently With, or after the shock occurs. Desired effects 
of treatment can include therapeutic effects and prophylactic 
effects. 
For example, if the treatment is affected before the event 
creating a risk of shock occurs, the treatment can be intended 
to produce prophylactic effects. For another example, if the 
treatment is affected concurrently With or after the event 
creating a risk of shock occurs, the treatment can also be 
intended to produce prophylactic effects. In such cases, treat 
ment could be intended to prevent or reduce the risk of shock, 
and/or prevent or reduce the risk of injuries resulting from 
such shock. 
For another example, if the treatment is affected concur 
rently With or after the shock occurs, the treatment can be 
intended to produce prophylactic and therapeutic effects, pre 
venting or reducing injuries resulting from shock, and curing 
or mitigating the shock, e. g., restoring mean arterial pressure 
and perfusion of organs and tissues. 
The methods of the present invention can make use of 
Delt-E and compositions containing Delt-E, and are useful in 
a variety of settings. For example, Delt-E treatment is useful 
in clinical settings Where planned surgeries are performed, 
including planned ischemia and other procedures. In this 
regard, it can be desirable to treat a subject Who Will undergo 
a planned ischemia or surgical procedure, prior to the occur 
rence of the procedure, because such procedures can result in 
hemorrhage, ischemia, and/or shock, i.e., affecting treatment 
before an event that creates a risk of shock using Delt-E as a 
pharmacological ischemic preconditioning agent Where 
ischemic events can be anticipated. Depending on the status 
of a subject undergoing a procedure, medical personnel could 
treat that subject after the procedure has been initiated, for 
example, When a risk of hemorrhage becomes apparent. For 
another example, Delt-E treatment is useful in an emergency 
room (ER) or an intensive care unit (ICU) setting. For another 
example, Delt-E treatment is useful in civilian trauma set 
tings, e.g., highWay accident scenes, or military trauma set 
tings. In this regard, Delt-E could be rapidly administered by 
?rst responders during the initial period folloWing trauma, 
When lifesaving intervention is often considered most critical. 
Depending on the status of a subject being treated in a trauma 
setting, a ?rst responder could treat that subject before the 
onset of shock, concurrently With the onset of shock, or after 
the onset of shock. Since large volumes of resuscitation ?u 
ids, Which are associated With knoWn methods of treatment, 
Would not be required When administering Delt-E, the 
method of the present invention is especially useful in a 
civilian or military trauma setting, Where large ?uid volumes 
Would be dif?cult to obtain, transport, or access. 
Delt-E can be administered prior to the onset of shock or 
prior to the occurrence of an event that creates a risk of shock, 
e.g., planned surgery. For example, in some embodiments, 
Delt-E can be administered up to about 24 hours prior to the 
onset of shock or prior to the occurrence of an event that 
creates a risk of shock. In some embodiments, Delt-E can be 
administered up to about 1, 2, 3, 4, 5, 10, 15, or 20 hours prior 
to the onset of shock or prior to the occurrence of an event that 
creates a risk of shock. Further, in some embodiments, Delt-E 
can be administered about 20 to about 24 hours prior to the 
onset of shock or prior to the occurrence of an event that 
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creates a risk of shock. In some embodiments, Delt-E can be 
administered about 15 to about 20 hours, about 10 to about 15 
hours, about 5 to about 10 hours, about 4 to about 5 hours, 
about 3 to about 4 hours, about 2 to about 3 hours, or about 1 
to about 2 hours prior to the onset of shock or the occurrence 
of an event that creates a risk of shock. 
Delt-E can be administered up to about 4 hours subsequent 
to the onset of shock or the occurrence of an event that creates 
a risk of shock. Delt-E can be administered up to about 1, 2, 
or 3 hours subsequent to the onset of shock or the occurrence 
of an event that creates a risk of shock. Delt-E can be admin 
istered concurrently With the onset of shock or the occurrence 
of an event that creates a risk of shock. 
Delt-E can be administered in accordance With the present 
invention in a variety of manners. A solution or an emulsion of 
Delt-E can be administered parenterally. A solution or an 
emulsion of Delt-E can be administered by intravenous inj ec 
tion, intraperitoneal injection, or intraarterial inj ection. A 
solution or an emulsion of Delt-E can be administered by 
direct injection into the brain, for example, intracerebroven 
tricular injection, for dispersion to other areas. Injection vol 
umes can be about 0.5 to about 2.0 milliliters. Delt-E can be 
administered in combination With other compounds, if 
desired. 
Actual dosage levels of Delt-E can be varied so as to 
administer an amount of Delt-E that is effective to achieve the 
desired therapeutic response for a particular subject and/or 
application. The selected dosage level Will depend upon a 
variety of factors including the activity of the therapeutic 
composition, formulation, the route of administration, com 
bination With other drugs or treatments, severity of the con 
dition being treated, the physical condition and prior medical 
history of the subject being treated, and the like. Preferably, a 
minimal dose is administered, and dose is escalated in the 
absence of dose-limiting toxicity to a minimally effective 
amount. Determination and adjustment of a therapeutically 
effective dose, as Well as evaluation of When and hoW to make 
such adjustments, are knoWn to those of ordinary skill in the 
art of medicine, and any necessary determinations in a par 
ticular case can be made by those of ordinary skill in the art 
using only routine experimentation. 
For administration of a composition as disclosed herein, 
conventional methods of extrapolating human dosage based 
on doses administered to a murine animal model can be 
carried out using the conversion factor for converting the 
mouse dosage to human dosage: Dose Human per kgIDose 
Mouse per kg><12 (Freireich et al., (1966) Cancer Chemother 
Rep. 50:219-244). Drug doses can also be given in milligrams 
per square meter of body surface area because this method, 
rather than body Weight, achieves a good correlation to cer 
tain metabolic and excretionary functions. Moreover, body 
surface area can be used as a common denominator for drug 
dosage in adults and children as Well as in different animal 
species as described by Freireich et al. (Freireich et al., (1966) 
Cancer Chemother Rep. 50:219-244). Brie?y, to express a 
mg/kg dose in any given species as the equivalent mg/ sq m 
dose, multiply the dose by the appropriate km factor. In an 
adult human, 100 mg/kg is equivalent to 100 mg/kg><37 kg/ sq 
m:3700 mg/m2. 
In certain embodiments, useful doses of Delt-E are from 
about 1 ug/kg to about 20 mg/kg of body Weight of the subject 
being treated. In certain embodiments of the invention, useful 
doses of Delt-E are from about 1-1000 ug/kg. In certain 
embodiments of the invention, useful doses of Delt-E are: 
from about 1 ug/kg to about 200 ug/kg, from about 200 ug/kg 
to about 250 ug/kg, from about 250 ug/kg to about 500 ug/kg, 
from about 500 ug/kg to about 750 ug/kg, from about 750 
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ug/kg to about 1000 ug/kg, from about 1 mg/kg to about 2 
mg/kg, from about 2 mg/kg to about 3 mg/kg, from about 3 
mg/kg to about 5 mg/kg, from about 5 mg/kg to about 10 
mg/kg, from about 10 mg/kg to about 15 mg/kg, and from 
about 15 mg/kg to about 20 mg/kg. 
For additional guidance regarding formulation and dose, 
see US. Pat. Nos. 5,326,902; 5,234,933; PCT International 
Publication No. WO 93/25521; BerkoW et al., (1997) The 
Merck Manual of Medical Information, Home ed. Merck 
Research Laboratories, Whitehouse Station, N.J.; Goodman 
et al., (1996) Goodman & Gilman's the Pharmacological 
Basis of Therapeutics, 9th ed. McGraW-Hill Health Profes 
sions Division, NeW York; Ebadi, (1998) CRC Desk Refer 
ence of Clinical Pharmacology. CRC Press, Boca Raton, 
Fla.; KatZung, (2001) Basic & Clinical Pharmacology, 8th 
ed. Lange Medical Books/McGraW-Hill Medical Pub. Divi 
sion, NeW York; Remington et al., (1975) Remington's Phar 
maceutical Sciences, 15th ed. Mack Pub. Co., Easton, Pa.; 
and Speight et al., (1 997) Avery's Drug Treatment: A Guide to 
the Properties Choice, Therapeutic Use and Economic Value 
of Drugs in Disease Management, 4th ed. Adis International, 
Auckland/Philadelphia; Duch et al., (1998) Toxicol. Lett. 
100-101:255-263. 
The present invention is further illustrated by the folloWing 
speci?c but non-limiting examples. The folloWing examples 
may include compilations of data that are representative of 
data gathered at various times during the course of develop 
ment and experimentation related to the present invention. 
EXAMPLES 
A murine hemorrhagic shock model Was used to evaluate 
the effects of administration of Deltorphin-E (Delt-E), With 
out concomitant ?uid resuscitation, on hemodynamic status, 
plasma lactate levels, and survival rates. 
Study Design: Post Hemorrhage Delt-E Infusion 
The hemorrhagic shock model used Was a volume-con 
trolled model similar to that of Summers et al. Acad Emerg 
Med. 10:587-93 (2003). Forty-six male Sprague-DaWley rats 
(about 341-41 1 grams) Were acclimated to a laboratory envi 
ronment for a Week. In dWelling hepariniZed PE 10 catheters 
Were placed in the femoral artery and the femoral vein of 
anesthetiZed rats. The tWo catheters Were combined and 
exited suprascapularly, tied in place With braided silk, and 
covered With a piece of hypoallergenic mesh to prevent kink 
ing. Rats Were then placed in recovery cages for 24 hr, 
alloWed access to food and Water, and alloWed unrestricted 
access to both catheters. The femoral artery catheter Was used 
for volume-controlled hemorrhage and blood pressure mea 
surements and the femoral vein catheter Was used for Delt-E 
infusion. Each selected animal Was randomly assigned 1 of 6 
post hemorrhage treat groups: 1 mL/100 g saline control 
(n:6), 2.85 mg/kg Delt-E (n:6), 4.2 mg/kg Delt-E (n:6), 5.5 
mg/kg Delt-E (n:6), and 14 mg/kg Delt-E (n:6). Animals 
Were also selected and randomly assigned to 1 of 4, 30-minute 
pre-treatment inhibitor groups: Naltriben Methane Sulfonate 
(N TB) (n:4), Naltrexone (n:4), Glibenclamide (n:4), and 
7-DehydrobenZylidine naltrexone (BNTX) (n:4) folloWed 
by a 5.5 mg/kg injection of Delt-E. 
Treatment: TWenty-four hours after catheter placement, 
test rats (n:24) Were infused in the femoral vein With either 
2.85, 4.2, 5.5 or 14 mg/kg of Delt-E (Tyr-D-Ala-Phe-Ala-Ile 
Gly-Asp-Phe-Ser-Ile-NH2; SEQ ID NO: 1) dissolved in 1.0 
ml Lactated Ringers (LR) solution pH 7.4. Control rats (n:6) 
Were infused With 1.0 ml Lactated Ringers solution pH 7.4. 
Prior to hemorrhage MAP and HR Were recorded to establish 
baseline levels. During hemorrhage approximately 48% of 
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the total blood volume Was removed at a rate of 3 mL/ 100 g 
over a 9- to 11-minute period. After the ?nal mL of blood Was 
removed the various venous catheter treatment injections 
Were administered, MAP and HR Were recorded continu 
ously for the duration of survival or up to 6 hours. 
Biomarker protocols: Survival time Was determined by the 
post hemorrhage time after injection until death, or a prede 
termined 360 minute survival interval. Death Was de?ned as 
systolic blood pressure Without pulsation, and apnea. Ani 
mals Were observed for several more minutes to ensure that 
autoresuscitation did not occur. Any animal surviving 360 
minutes Was sacri?ced according to our protocol With ure 
thane (1.0 g/kg, Sigma Aldrich). This Was done to minimiZe 
any discomfort to the animal and also because reportedly 
D-Alanine deltrophins exhibit plasma half-lives of six hours 
(Marastoni et al. 1991). Plasma lactate levels Were deter 
mined from arterial samples at the beginning of hemorrhage 
(BOH) and 10 min after end of hemorrhage (EOH) and 
venous catheter injection utiliZing a Vitros® 950 Chemistry 
AnalyZer (Ortho-Clinical Diagnostics, Rochester, N.Y.). 
Pulse pressure Was determined by the difference (mmHg) 
betWeen the systolic and diastolic pressure during a single 
cardiac cycle. A total of six measurements for each treatment 
group Were taken after venous catheter injection at a fre 
quency of one every ?ve minutes for ?rst 30 minutes. 
Opioid Inhibitors: The opioid inhibitors (naltrexone, nal 
triben methane sulfonate (NTB) and 7 DehydrobenZylidine 
naltrexone (BNTX) and Glibenclamide Were administered 30 
minutes prior to hemorrhage. MAP and HR Were recorded 
continuously before hemorrhage to ensure no adverse affects 
on MAP or HR occurred as a result of the pre-inj ection. At the 
end of 30 minutes, volume-controlled hemorrhage Was 
induced folloWed by a post hemorrhage injection of 5.5 
mg/kg Delt-E, the optimal dose found to increase hemody 
namic stability. Naltrexone (10 mg/kg, Sigma-Aldrich), NTB 
(1 mg/kg, Sigma-Aldrich), and BNTX (1 mg/kg, Tocris Bio 
science) Were used as 30 minute pre-inj ection opioid receptor 
antagonists. Glibenclamide (10 mg/kg, Sigma Aldrich) Was 
used as a K ATP channel blocker. 
Data Analysis: Statistical analysis Was preformed using 
SPSS softWare With P value <0.05 being considered signi? 
cant. The survival, MAP, HR and lactic acid values Were 
analyZed using repeated measures analysis of variance 
(ANOVA) betWeen groups to identify differences betWeen 
groups. To evaluate differences betWeen means, the ANOVA 
With post hoc least square differences Were used (LSD analy 
sis). 
The steady state changes in MAP and HR Were ?tted to a 
sigmoid logistic equation, plotted, and derivative of the equa 
tion Were used to obtain the upper and loWer plateaus and 
create curves that re?ect instantaneous change as Well as the 
BPSO, the MAP halfWay betWeen upper and loWer plateaus 
(Flynn F W and Stricker 2003; Head and McCarty 1987, 
McBride et al., 2005) Were employed. The average heart rate 
gain, or slope of the curve betWeen the upper and loWer 
in?ection points Was derived from coef?cients of the logistic 
equation and re?ects the greatest sensitivity of the barore?ex 
(Head and McCarty 1987). 
Results: The MAP at the beginning (11211.9 mmHg) or 
end (3310.63 mmHg) of hemorrhage Was not signi?cantly 
different betWeen any of the treatment groups using repeated 
measures ANOVA. With reference to FIG. 1, the 5.5 mg/kg 
Delt-E post treatment group Was signi?cantly (P<0.01) 
higher When compared With the saline control group during 
the entire interval examined. The 14.0 mg/kg dose of Delt-E 
Was found to be toxic and thus is excluded from all ?gures as 
seen in Table 1. With reference to FIG. 1 and Table 1, the max 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
14 
MAP recorded during recovery post hemorrhage Was signi? 
cantly higher for 2.9 mg/kg (P<0.05), 4.2 mg/kg (P<0.05), 
and 5 .5 mg/kg (P<0.01) treated Delt-E group versus the saline 
control group, 50117 mmHg, 53111 mmHg, and 5817 
mmHg vs. 3519 mmHg respectively. HoWever, mean heart 
rate trended doWnWard for both groups With no signi?cant 
difference in heart rate betWeen the control group and any 
Delt-E treated group. 
TABLE 1 
Delt-E Dose Response Comparison of Hemodynamic Biomarkers. 
Group (n) Survival Time Maximum MAP Maximum HR 
(dose) in minutes 1 S.E. in mmHg 1 S.E. in BPM 1 S.E. 
Saline (6) 50 1 8 35 1 9 425 1 94 
(1 mL/100 
g control) 
Delt-E (6) 107 111** 50 117* 432 1 79 
(2.9 mgkg) 
Delt-E (6) 232 114** 53 111* 403 1 65 
(4.2 mgkg) 
Delt-E (6) 331118**TT 58 1 7** 396 1 40 
(5.5 mgkg) 
Delt-E (6) 27 1 7 51 115* 394 1 79 
(14.0 mg/kg) 
J[*[Rats sacri?ced at six hours. 
*P < 0.05 compared With saline controls 
**P < 0.01 compared With saline controls. 
(n) = number of animals per treatment group 
Legend: MAP = mean arterial pressure and BPM = beats per minute. 
Repeated-measures ANOVA revealed statistically signi?cant differences in 
survival time distributions, and maximum MAP distributions between the 
control and Delt-E groups. Post-Hoc measurements shoWed signi?cant 
increase in survival time in both the 4.2 mg/kg and 5.5 mgkg Delt-E treated 
groups. MAP Was also signi?cantly improved in both the 4.2 and 5.5 mgkg 
Delt-E treated group. There Was no signi?cance difference seen in the Heart 
Rate maximum BPM between any of test groups. 
With reference to FIG. 2 and Table 1, repeated-measures 
ANOVA revealed a signi?cant (P<0.01) increase in survival 
time for the 2.9 mg/kg, 4.2 mg/kg, and 5.5 mg/kg Delt-E 
treated group versus the control group (10711 min, 232114 
min, and 331118 min vs. 5018 min, respectively. 
With reference to FIG. 3, Delt-E did not signi?cantly alter 
the average BP5O or average HR gain at the 5.5 mg/kg Delt-E 
dose. The 5.5 mg/kg Delt-E dose is the most effective in 
restoring hemodynamic parameters post hemorrhage When 
compared With saline. 
With reference to FIG. 4, mean lactic acid levels at the end 
of hemorrhage for saline controls increased 6-fold to 
88810.1 mmol/L, and four-fold for 5.5 mg/kg Delt-E treated 
animals to 6541154 mmol/L. The 5.5 mg/kg Delt-E treated 
group Was the only group that had a signi?cantly loWer lactic 
acid level (p>0.01) than the saline control group. 
With reference to FIG. 5, post hemorrhage injections of 
Delt-E signi?cantly (P<0.01) increased pulse pressure 
(mmHg systolic-mmHg diastolic) for the 2.9 mg/kg, 4.2 
mg/kg, and 5.5 mg/kg Delt-E treated group versus the saline 
control group (4210.37 mmHg, 4410.4 mmHg, and 4810.56 
mmHg vs. 3810.44 mmHg respectively) in a dose dependent 
manner (P<0.01). 
With reference to FIG. 6, comparison of Delt-E mediated 
survival time versus pH post hemorrhage shoWed a signi?cant 
(R2:0.929) dose response correlation betWeen the decrease 
in pH and increase in survival time. For every 0.1 decrease in 
pH there is a 12.5 minute increase in survival time. 
Naltrexone, the universal opioid antagonist of mu, kappa, 
and 6 opioid receptors and the speci?c 62 receptor antagonist 
NTB blocked the post hemorrhage hemodynamic recovery 
bene?ts of 5.5 mg/kg Delt-E as seen in Table 2. BNTX the 61 
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speci?c opioid antagonist, on the other hand, did not block the 
5 .5 mg/kg Delt E improvement in survival and MAP recovery 
as seen in Table 2. 
TABLE 2 
Hemodynamic Biomarker Response to 30 minute Inhibitor Pre-treatment 
ofInhibitors Before 5.5 mg/kg Delt-E Post Hemorrhage Iniection 
Group (11) Survival Time Maximum MAP Maximum HR 
(dose) in minutes 1 SE. in mmHg 1 SE. in BPM 1 SE 
Saline (6) 50 1 8 35 1 9 425 1 94 
(1 mL/100 g 
control) 
NTB(4) 58112 37113 423168 
(1 mg/kg) 
Naltrexone (4) 95 1 11** 49 1 8* 419 1 75 
(10 Ing/kg) 
Glibenclamide (4) 347 1 15**TT 56 1 10** 393 1 43 
(10 Ing/kg) 
BNTX (4) 356 1 3**TT 55 112** 400 1 77 
(1 mg/kg) 
Delt-E (6) 331 118**TT 58 1 7** 396 1 40 
(5.5 mg/kg) 
J[TRats sacri?ced at six hours 
*P < 0.05 compared with saline controls 
**P < 0.01 compared with saline controls. 
(n) = number of animals per treatment group 
Legend: Repeated-measures ANOVA revealed no signi?cant differences 
from controls when treatment with Naltrexone or Naltriben preceeded Delt E 
intervention;. However, signi?cant differences in survival time and maxi 
mum MAP similar to Delt E alone group were found when glibenclamide or 
BNTX preceeded Delt E treatment. Therefore neither glibenclaminde nor 
BNTX interfered with the Delt E advantage. No signi?cance difference was 
seen in maximum BPM between any ofthe test groups. *P < 0.05. **P < 
0.01. 
Similarly, Glibenclamide did not alter the survival advan 
tage of post treatment with Delt E since repeated-measures 
ANOVA revealed no statistically signi?cant differences in 
survival time distributions, and maximum MAP distributions 
between the pre-treated Glibenclamide and Delt-E alone 
groups as seen in Table 2. 
Discussion: These studies demonstrated that Delt-E 
administration without accompanying ?uid resuscitation 
immediately after severe hemorrhage resulted in ischemic 
protection, which included improvement in hemodynamic 
stability markers including increased MAP, decreased HR, 
increased pulse pressure (i.e. difference between systolic and 
diastolic pressure), decreased plasma lactate production, and 
increased survival time. The effects of speci?c opioid recep 
tor sites activated by Delt-E were assessed by the response of 
Naltrexone (a universal opioid receptor inhibitor) and BNTX 
(a delta 1 speci?c opioid inhibitor) and NTB (a delta2 speci?c 
opioid receptor inhibitor) on hemodynamic markers in 
severely hemorrhaged rats. The role of K ATP channel activa 
tion was determined by the use of the non-speci?c K ATP 
channel blocker, Glibenclamide. 
Post-hemorrhage treated controls (1 mL/ 100 g i.v. saline) 
exhibited maximum MAP (i.e., 3519 mmHg), maximum HR 
(i.e., 425194 bpm), lactic acid concentration of 8.910.12 
mmol/L, and pulse pressure of38.310.44 mmHg. In contrast, 
post-hemorrhage 5.5 mg/kg Delt-E treated rates exhibited 
maximum MAP (5817 mmHg) and maximum HR (396140 
bpm), lactic acid (6.511.2 mmol/L) and pulse pressure 
(47.910.55 mmHg). At the 5.5 mg/kg dose Delt-E treated 
animals lived at least six times longer (331 minutes) versus 
the saline control animals (50 minutes), P<0.01 signi?cance. 
Using logistic analysis of MAP-HR gain suggests Delt-Eva, 
did not signi?cantly alter the barore?ex sensitivity. However, 
Delt-E facilitates a cardioprotective effect post-hemorrhage 
through alternate pathways involving lactic acid reduction. A 
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dose response correlation between lactic acid concentration 
and increased survival was found. It is possible that delta2 
speci?c opioid receptor agonists such as Delt-E and Deltor 
phin-DWm-am (Delt-Dvar) may induce a hibemation-like state 
of metabolic depression following severe hemorrhage, 
thereby, retarding the anaerobic glycolytic pathway which is 
known to be increased resulting in decreased levels of circu 
lating lactate. Delt-E may also facilitate a cardioprotective 
recompensatory recovery mechanism following hemorrhage 
which entails Delt-E’s pulse pressure. The greater the 
increase in pulse pressure, the greater the survival. The role of 
pulse pressure in ischemic stress response has not been fully 
characterized. However, in humans it is known that exercise 
induced stress can alter pules pressure which increase stroke 
volume and cardiac output leading to greater tissue perfusion. 
Following injections of Delt-E there was a signi?cant 
increase in pulse pressure with a dose related response lead 
ing to greater tissue perfusion. Delt-E also dose dependently 
enhanced MAP recovery and length of survival following 
severe hemorrhage as had been previously demonstrated in 
rats infused with Delt-Dvar24 hrprior to severe (53%) volume 
controlled hemorrhage (Oeltgen et. al 2006). 
To further clarify the cellular mechanisms by which acti 
vation of the 62 opioid receptor by Delt-E produces hemody 
namic recovery in rat, we studied the role of GM proteins and 
the K ATP channel in mediating this effect. It has been well 
documented in several tissue types that the o-opioid receptor 
is linked to K” channels via G proteins (Musser et al. 2004). 
Wild et al. (1991) demonstrated that activation of the o-opioid 
receptor via K” channels produced a cardioprotective effect 
and the subtypes of this receptor were linked to different K” 
channels. Their results demonstrated that the cardioprotective 
effect produced by the ol-opioid receptor agonist DPDPE 
could be negated by Glibenclamide, indicting that the 61 
receptor subtype was linked to neuronal K A H, channels. How 
ever, the cardioprotective effect of Deltorphin II, a 62 opioid 
receptor agonist, was not blocked by Glibenclamide, which 
demonstrates that the 62 receptor subtype is linked to voltage 
gated K” channels and not to K ATP channels (Wild et al. 
1991). Our present results further demonstrated that the car 
dioprotection provided by Delt-E, a 6 agonist, was not 
blocked by Glibenclamide indicating that the hemodynamic 
recovery protection is mediated by a mechanism not involv 
ing K ATP channels, but perhaps by a voltage-gated K” chan 
nel. 
The universal antagonist Naltrexone partially blocked the 
hemodynamic recovery effects of Delt-E indicating that 
Delt-E was acting upon a 6 opioid receptor. Further investi 
gation with speci?c delta opioid receptor agonists (N TB (62) 
and BNTX (61) revealed that only the 62 opioid receptor 
agonists NTB blocked Delt-E’s effect on shock and survival 
following severe hemorrhage. Therefore, the site of action for 
Delt-E is a 62 opioid receptor which, following intravenous 
administration, promotes signi?cant recovery of hemody 
namic biomarkers after severe hemorrhage. 
The studies described herein indicate that Delt-E adminis 
tration after the occurrence of an event creating a risk of 
circulatory and hypovolemic shock is an effective treatment. 
The treatment provides protection against hemorrhage and 
facilitates recovery. 
Study Design: Prehemorrhage Delt-E Infusion 
The hemorrhagic shock model used was a volume-con 
trolled model similar to that of Summers et al. Acad Emerg 
Med. 10:587-93 (2003). Twenty male Sprague-Dawley rats 
(about 325-400 grams) were acclimated to a laboratory envi 
ronment for a week, and then randomly assigned to one of two 
groups, controls (n:14) and Delt-E treated group (n:5). In 






